JP7384819B2 - 癌の予防及び治療のための抗原性ペプチド - Google Patents

癌の予防及び治療のための抗原性ペプチド Download PDF

Info

Publication number
JP7384819B2
JP7384819B2 JP2020555892A JP2020555892A JP7384819B2 JP 7384819 B2 JP7384819 B2 JP 7384819B2 JP 2020555892 A JP2020555892 A JP 2020555892A JP 2020555892 A JP2020555892 A JP 2020555892A JP 7384819 B2 JP7384819 B2 JP 7384819B2
Authority
JP
Japan
Prior art keywords
seq
antigenic peptide
fragment
amino acid
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020555892A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520818A5 (https=
JP2021520818A (ja
Inventor
ローラン・シェーヌ
クリストフ・ボニー
フランチェスコ・ストロッツィ
Original Assignee
エンテローム エスエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンテローム エスエー filed Critical エンテローム エスエー
Publication of JP2021520818A publication Critical patent/JP2021520818A/ja
Publication of JP2021520818A5 publication Critical patent/JP2021520818A5/ja
Priority to JP2023191203A priority Critical patent/JP7670445B2/ja
Application granted granted Critical
Publication of JP7384819B2 publication Critical patent/JP7384819B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001119—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020555892A 2018-04-11 2019-04-11 癌の予防及び治療のための抗原性ペプチド Active JP7384819B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023191203A JP7670445B2 (ja) 2018-04-11 2023-11-09 癌の予防及び治療のための抗原性ペプチド

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18305444.4 2018-04-11
EP18305444 2018-04-11
EPPCT/EP2018/077512 2018-10-09
EP2018077512 2018-10-09
PCT/EP2019/059329 WO2019197567A2 (en) 2018-04-11 2019-04-11 Antigenic peptides for prevention and treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023191203A Division JP7670445B2 (ja) 2018-04-11 2023-11-09 癌の予防及び治療のための抗原性ペプチド

Publications (3)

Publication Number Publication Date
JP2021520818A JP2021520818A (ja) 2021-08-26
JP2021520818A5 JP2021520818A5 (https=) 2022-04-11
JP7384819B2 true JP7384819B2 (ja) 2023-11-21

Family

ID=66092357

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020555892A Active JP7384819B2 (ja) 2018-04-11 2019-04-11 癌の予防及び治療のための抗原性ペプチド
JP2023191203A Active JP7670445B2 (ja) 2018-04-11 2023-11-09 癌の予防及び治療のための抗原性ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023191203A Active JP7670445B2 (ja) 2018-04-11 2023-11-09 癌の予防及び治療のための抗原性ペプチド

Country Status (19)

Country Link
US (2) US12016910B2 (https=)
EP (2) EP3773689B1 (https=)
JP (2) JP7384819B2 (https=)
CN (2) CN120535570A (https=)
AU (1) AU2019253217B2 (https=)
BR (1) BR112020020780A2 (https=)
CA (1) CA3094262A1 (https=)
DK (1) DK3773689T5 (https=)
ES (1) ES2935702T3 (https=)
FI (1) FI3773689T3 (https=)
HR (1) HRP20230007T1 (https=)
HU (1) HUE060791T2 (https=)
LT (1) LT3773689T (https=)
MX (2) MX2020010701A (https=)
PL (1) PL3773689T3 (https=)
RS (1) RS63873B1 (https=)
SI (1) SI3773689T1 (https=)
SM (1) SMT202300021T1 (https=)
WO (1) WO2019197567A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
WO2018065623A2 (en) 2016-10-07 2018-04-12 Enterome Immunogenic compounds for cancer therapy
CN110022894B (zh) 2016-10-07 2024-01-19 恩特罗姆公司 用于癌症疗法的免疫原性化合物
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
MX2022004598A (es) * 2019-10-16 2022-09-23 Enterome S A Compuestos inmunogenicos para el tratamiento del cancer suprarrenal.
FI4021487T3 (fi) * 2019-11-15 2024-02-06 Enterome S A Antigeenisiä peptidejä b-solun pahanlaatuisuuden ehkäisyyn ja hoitoon
CN111197040B (zh) * 2020-01-21 2023-08-08 福建亿彤生物科技有限公司 壳多糖酶3样蛋白1（chi3l1）抗原表位肽、抗原、抗体、用途及试剂盒
CN114163511B (zh) * 2021-03-24 2025-02-25 深圳市新靶向生物科技有限公司 一种与肝癌驱动基因突变相关的抗原肽组合及其应用
AU2023246941A1 (en) * 2022-03-31 2024-10-24 Enterome S.A. Antigenic peptides for prevention and treatment of cancer.
IT202200006785A1 (it) * 2022-04-06 2023-10-06 Istituto Naz Tumori Irccs Fondazione G Pascale Analoghi di antigeni tumorali da microbiota e usi relativi
KR20240017325A (ko) * 2022-07-29 2024-02-07 주식회사 엘지화학 항원 전달용 재조합 융합 단백질 및 이의 이용

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517529A (ja) 2003-01-30 2006-07-27 スルヴァック・アンパルトセルスカブ スルビビン誘導ペプチドおよびその使用
JP2013509452A (ja) 2009-11-03 2013-03-14 コリア・ユニバーシティ・リサーチ・アンド・ビジネス・ファウンデーション 酸化亜鉛−結合性ペプチドを含むタンパク質と酸化亜鉛ナノ粒子の複合体及びその用途
WO2013135553A1 (en) 2012-03-16 2013-09-19 Invectys Universal cancer peptides derived from telomerase
JP2014193893A (ja) 2007-08-20 2014-10-09 Oncotherapy Science Ltd Ｆｏｘｍ１ペプチドおよびこれを含む薬剤
JP2014239681A (ja) 2008-10-01 2014-12-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法
JP2015518835A (ja) 2012-05-16 2015-07-06 ステムライン セラピューティクス，インコーポレーテッド 癌幹細胞を標的とした癌ワクチン
WO2016146259A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for treatment of glioblastoma
JP2016530290A (ja) 2013-09-06 2016-09-29 アルティミューン ユーケー リミテッド 腫瘍学ワクチン
JP2017014221A (ja) 2010-08-24 2017-01-19 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション インターロイキン−１３受容体α２ペプチド脳がんワクチン
JP2017518375A (ja) 2014-06-06 2017-07-06 ヘアレウ ホスピタル Ｍｈｃ多量体のバーコード標識による抗原認識の判定

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5550214A (en) 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ATE459373T1 (de) 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
ATE512666T1 (de) 1999-06-29 2011-07-15 Epimmune Inc Hla-bindende peptide und ihre verwendungen
FR2798128B1 (fr) 1999-09-06 2001-11-16 Inst Nat Sante Rech Med Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
CA2400215A1 (en) 2000-02-23 2001-08-30 Epimmune Inc. Hla binding peptides and their uses
WO2003092717A1 (en) 2002-03-22 2003-11-13 The Penn State Research Foundation Cancer immunotherapy
CA2500715A1 (en) 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
CN1954217B (zh) 2004-02-06 2013-05-08 国立健康与医学研究所 衍生自gp41的多肽、含有所述多肽的疫苗组合物以及用于治疗个体HIV病毒感染的用途
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
BRPI0720280A2 (pt) 2006-12-11 2014-01-28 Wyeth Corp Métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13
ES2532896T5 (es) 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
WO2010018136A1 (en) 2008-08-12 2010-02-18 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
WO2010129033A2 (en) 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
WO2011140284A2 (en) 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
WO2013101690A1 (en) 2011-12-29 2013-07-04 modeRNA Therapeutics Modified mrnas encoding cell-penetrating polypeptides
EP2828664B1 (en) 2012-03-19 2018-09-26 Stemline Therapeutics Inc. Methods for treating and monitoring the status of cancer
WO2013148147A1 (en) 2012-03-26 2013-10-03 The U.S.A., As Represented By The Secretary Dept. Of Health And Human Services Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US20140141044A1 (en) 2012-11-12 2014-05-22 Dana-Farber Cancer Institute, Inc. Cord Colitis Syndrome Pathogen
US9758807B2 (en) 2012-12-05 2017-09-12 SOLA Biosciences, LLC Protein expression enhancing polypeptides
WO2014088432A1 (en) 2012-12-06 2014-06-12 Callaghan Innovation Research Limited Conjugate compounds
US20180078627A1 (en) 2015-03-31 2018-03-22 Agency For Science, Technology And Research Method for antigen loading of dendritic cells and vaccine
BR112018005581A2 (pt) 2015-10-08 2018-10-16 Oncotherapy Science, Inc. peptídeo derivado de foxm1 e vacina incluindo o mesmo
US12018331B2 (en) 2016-05-23 2024-06-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of diagnosing cancer using cancer testis antigens
WO2018065623A2 (en) 2016-10-07 2018-04-12 Enterome Immunogenic compounds for cancer therapy
CN110022894B (zh) 2016-10-07 2024-01-19 恩特罗姆公司 用于癌症疗法的免疫原性化合物
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
KR102823291B1 (ko) 2017-10-09 2025-06-19 엔터롬 에스.에이. 종양-관련된 항원 에피토프의 미생물 서열 변이체
US20210106652A1 (en) 2018-04-11 2021-04-15 Enterome S.A. Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
MX2022004598A (es) 2019-10-16 2022-09-23 Enterome S A Compuestos inmunogenicos para el tratamiento del cancer suprarrenal.
FI4021487T3 (fi) 2019-11-15 2024-02-06 Enterome S A Antigeenisiä peptidejä b-solun pahanlaatuisuuden ehkäisyyn ja hoitoon

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517529A (ja) 2003-01-30 2006-07-27 スルヴァック・アンパルトセルスカブ スルビビン誘導ペプチドおよびその使用
JP2014193893A (ja) 2007-08-20 2014-10-09 Oncotherapy Science Ltd Ｆｏｘｍ１ペプチドおよびこれを含む薬剤
JP2014239681A (ja) 2008-10-01 2014-12-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法
JP2013509452A (ja) 2009-11-03 2013-03-14 コリア・ユニバーシティ・リサーチ・アンド・ビジネス・ファウンデーション 酸化亜鉛−結合性ペプチドを含むタンパク質と酸化亜鉛ナノ粒子の複合体及びその用途
JP2017014221A (ja) 2010-08-24 2017-01-19 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション インターロイキン−１３受容体α２ペプチド脳がんワクチン
WO2013135553A1 (en) 2012-03-16 2013-09-19 Invectys Universal cancer peptides derived from telomerase
JP2015518835A (ja) 2012-05-16 2015-07-06 ステムライン セラピューティクス，インコーポレーテッド 癌幹細胞を標的とした癌ワクチン
JP2016530290A (ja) 2013-09-06 2016-09-29 アルティミューン ユーケー リミテッド 腫瘍学ワクチン
JP2017518375A (ja) 2014-06-06 2017-07-06 ヘアレウ ホスピタル Ｍｈｃ多量体のバーコード標識による抗原認識の判定
WO2016146259A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for treatment of glioblastoma

Also Published As

Publication number Publication date
US12016910B2 (en) 2024-06-25
MX2023014457A (es) 2023-12-15
CN120535570A (zh) 2025-08-26
CA3094262A1 (en) 2019-10-17
HUE060791T2 (hu) 2023-04-28
PL3773689T3 (pl) 2023-03-13
DK3773689T3 (da) 2023-01-16
EP4169528A1 (en) 2023-04-26
SMT202300021T1 (it) 2023-03-17
EP3773689B1 (en) 2022-11-09
US20240293520A1 (en) 2024-09-05
ES2935702T3 (es) 2023-03-09
FI3773689T3 (fi) 2023-01-31
US20210113678A1 (en) 2021-04-22
CN112118863A (zh) 2020-12-22
SI3773689T1 (sl) 2023-02-28
CN112118863B (zh) 2025-05-30
HRP20230007T1 (hr) 2023-03-03
MX2020010701A (es) 2021-01-20
WO2019197567A3 (en) 2019-11-28
BR112020020780A2 (pt) 2021-03-02
LT3773689T (lt) 2023-01-25
JP7670445B2 (ja) 2025-04-30
JP2024016203A (ja) 2024-02-06
AU2019253217B2 (en) 2025-09-25
DK3773689T5 (da) 2024-08-19
RS63873B1 (sr) 2023-02-28
JP2021520818A (ja) 2021-08-26
WO2019197567A2 (en) 2019-10-17
AU2019253217A1 (en) 2020-10-15
EP3773689A2 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
JP7670445B2 (ja) 癌の予防及び治療のための抗原性ペプチド
JP7331207B2 (ja) 癌治療のための免疫原性化合物
US11759508B2 (en) Antigenic peptides for treatment of B-cell malignancy
US20230080443A1 (en) Immunogenic compounds for cancer therapy
JP2025511086A (ja) 癌の防止及び処置のための抗原性ペプチド
RU2812911C2 (ru) Антигенные пептиды для профилактики и лечения рака

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220401

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220527

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230926

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231010

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231109

R150 Certificate of patent or registration of utility model

Ref document number: 7384819

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150